Nishtha Sodhi, MD
Cardiovascular Disease · Saint Paul, MNNPI 1467744326
Payments from drug & device makers
Across 195 payments — averaging $589.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- W. L. Gore & Associates, Inc.$64K
- Medtronic$27K
- Edwards Lifesciences$11K
- Ethicon Endo-surgery Inc.$7K
- Boston Scientific$3K
- Abbott$3K
- plus $505 from 4 others
What the payments were for
- Consulting fees$10,69521%
- Speaking & faculty fees$23,01346%
- Travel & lodging$9,60119%
- Food & beverage$6,59613%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| W. L. Gore & Associates, Inc. | 25 | $64,281 |
| Medtronic(2 entities) | 63 | $27,452 |
| Edwards Lifesciences | 62 | $10,950 |
| Ethicon Endo-surgery Inc. | 1 | $6,545 |
| Boston Scientific | 5 | $2,719 |
| Abbott | 33 | $2,519 |
| Philips North America LLC | 3 | $332 |
| Shockwave Medical, Inc | 1 | $80 |
| AstraZeneca | 1 | $78 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- COREVALVE EVOLUT R$19,093
- DERMABOND PRINEO$6,545
- STRATAFIX$6,545
- CoreValve Evolut$5,891
- EVOQUE$2,888
- GENERAL VASCULAR ACCESS$2,500
- Mitra Clip system$1,065
- Edwards SAPIEN 3 Transcatheter Heart Valve$756
- (6346) Intrasight Mobile$203
- PASCAL$185
- MitraClip$148
- Xience V coronary stent system$146
- LOTUS EDGE$123
- SAPIEN 3 Ultra RESILIA$119
- Tendyne Mitral Valve System$101
- Cardiovascular- Research only$101
- Edwards SAPIEN 3 Ultra Transcatheter Heart Valve$101
How this compares
$114,971 in reported general payments places this provider in the 80th percentile of 451 cardiovascular disease providers in Minnesota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 37 | $54,901 |
| Metoprolol Succinate | 31 | $493 |
| ClopidogrelClopidogrel Bisulfate | 29 | $442 |
| Atorvastatin Calcium | 16 | $305 |
| Nitroglycerin | 26 | $270 |
| Metoprolol Tartrate | 13 | $191 |
| Amlodipine Besylate | 11 | $180 |
| Lisinopril | 12 | $168 |
| Furosemide | 12 | $26 |
Paid to pharmacies, not to this prescriber.
Other cardiovascular disease in Saint Paul
- Leslie ForgoshSaint Paul$6.2M
- Alan BankSaint Paul$669K
- Thomas BiggsSaint Paul$244K
- Pierce VatterottSaint Paul$195K
- Jae OhRochester$7.9M
- Yogesh ReddyRochester$7.9M
- Mayra GuerreroRochester$7.1M
- Martha GroganRochester$6.3M
- Jeffrey ChambersMinneapolis$3.6M
- Mackram EleidRochester$3.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.